These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30597357)

  • 1. Update on the pathology of liver neoplasms.
    Matsukuma KE; Yeh MM
    Ann Diagn Pathol; 2019 Feb; 38():126-137. PubMed ID: 30597357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pathology of liver tumors].
    Schirmacher P
    Internist (Berl); 2020 Feb; 61(2):131-139. PubMed ID: 31953548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathology of combined hepatocellular-cholangiocarcinoma.
    Yeh MM
    J Gastroenterol Hepatol; 2010 Sep; 25(9):1485-92. PubMed ID: 20796144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the molecular pathogenesis, diagnosis and treatment of fibrolamellar hepatocellular carcinoma: A state of art review of the current literature.
    Alshareefy Y; Shen CY; Prekash RJ
    Pathol Res Pract; 2023 Aug; 248():154655. PubMed ID: 37429175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma.
    Vyas M; Hechtman JF; Zhang Y; Benayed R; Yavas A; Askan G; Shia J; Klimstra DS; Basturk O
    Mod Pathol; 2020 Apr; 33(4):648-656. PubMed ID: 31676785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathology of a benign bile duct lesion in the liver: Morphologic mimicker or precursor of intrahepatic cholangiocarcinoma.
    Lee KB
    Clin Mol Hepatol; 2016 Sep; 22(3):400-405. PubMed ID: 27729636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms.
    Abe N; Watanabe T; Izumisato Y; Suzuki Y; Masaki T; Mori T; Sugiyama M; Fusco A; Atomi Y
    J Gastroenterol; 2003; 38(12):1144-9. PubMed ID: 14714251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytologic features of fibrolamellar carcinoma with mucin production: a rare variant of combined hepatocellular-cholangiocarcinoma.
    Rosa M; Mohammadi A
    Diagn Cytopathol; 2014 May; 42(5):431-5. PubMed ID: 23008149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.
    Sasaki M; Matsubara T; Kakuda Y; Sato Y; Nakanuma Y
    Am J Surg Pathol; 2014 Mar; 38(3):364-9. PubMed ID: 24487593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic adenoma and focal nodular hyperplasia.
    Shortell CK; Schwartz SI
    Surg Gynecol Obstet; 1991 Nov; 173(5):426-31. PubMed ID: 1658955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of cell adhesion molecule CD44 in primary tumors of the liver: an immunohistochemical study.
    Washington K; Telen MJ; Gottfried MR
    Liver; 1997 Feb; 17(1):17-23. PubMed ID: 9062875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging approach to hepatocellular carcinoma, cholangiocarcinoma, and metastatic colorectal cancer.
    Fowler KJ; Saad NE; Linehan D
    Surg Oncol Clin N Am; 2015 Jan; 24(1):19-40. PubMed ID: 25444467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarcomatoid combined hepatocellular-cholangiocarcinoma: a case report and review of literature.
    Chin S; Kim Z
    Int J Clin Exp Pathol; 2014; 7(11):8290-4. PubMed ID: 25550887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma.
    Wakasa T; Wakasa K; Shutou T; Hai S; Kubo S; Hirohashi K; Umeshita K; Monden M
    Hepatogastroenterology; 2007 Mar; 54(74):508-13. PubMed ID: 17523309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tumor grading of the hepatobiliary system].
    Jütte H; Tannapfel A
    Pathologe; 2016 Jul; 37(4):299-303. PubMed ID: 27342594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation of mass-forming intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma: based on the multivariate analysis of contrast-enhanced computed tomography findings.
    Zhao YJ; Chen WX; Wu DS; Zhang WY; Zheng LR
    Abdom Radiol (NY); 2016 May; 41(5):978-89. PubMed ID: 27193795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.
    Akiba J; Nakashima O; Hattori S; Tanikawa K; Takenaka M; Nakayama M; Kondo R; Nomura Y; Koura K; Ueda K; Sanada S; Naito Y; Yamaguchi R; Yano H
    Am J Surg Pathol; 2013 Apr; 37(4):496-505. PubMed ID: 23388123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression.
    Ikeda H; Sato Y; Yoneda N; Harada K; Sasaki M; Kitamura S; Sudo Y; Ooi A; Nakanuma Y
    Hum Pathol; 2012 Nov; 43(11):1955-63. PubMed ID: 22516245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synchronous hepatocellular carcinoma and cholangiocarcinoma arising in two different dysplastic nodules.
    Kwon Y; Lee SK; Kim JS; Ro JY; Yu E
    Mod Pathol; 2002 Oct; 15(10):1096-101. PubMed ID: 12379757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular cancer, cholangiocarcinoma, and metastatic tumors of the liver.
    Petrelli NJ
    Surg Oncol Clin N Am; 2015 Jan; 24(1):xi-xii. PubMed ID: 25444477
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.